Free Trial
→ A gold storm is coming – are you ready? (From Traders Agency) (Ad)tc pixel Free UNCY Stock Alerts

Unicycive Therapeutics (UNCY) Financials

Unicycive Therapeutics logo
$7.20 -0.03 (-0.41%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$7.16 -0.04 (-0.57%)
As of 06/3/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Unicycive Therapeutics

Annual Income Statements for Unicycive Therapeutics

This table shows Unicycive Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -2.26 -10 -18 -31 -38
Consolidated Net Income / (Loss)		 -2.26 -10 -18 -31 -37
Net Income / (Loss) Continuing Operations		 -2.26 -10 -18 -31 -37
Total Pre-Tax Income 		-2.26 -10 -18 -31 -37
Total Operating Income		 -2.02 -8.98 -18 -21 -32
Total Gross Profit		 0.00 0.00 0.95 0.68 0.00
Total Revenue		 0.00 0.00 0.95 0.68 0.00
Operating Revenue		 - 0.00 0.95 0.68 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.02 8.98 19 21 32
Selling, General & Admin Expense		 1.01 2.90 6.57 8.55 12
Research & Development Expense		 1.02 6.08 12 13 20
Total Other Income / (Expense), net		 -0.24 -1.04 -0.01 -9.77 -4.61
Interest Expense		 0.24 0.61 0.01 0.08 0.07
Interest & Investment Income		 - - 0.00 0.62 1.26
Other Income / (Expense), net		 0.00 -0.43 -0.01 -10 -5.80
Preferred Stock Dividends Declared		 - - 0.00 0.87 1.10
Basic Earnings per Share		 ($0.27) ($0.86) ($1.20) ($1.28) ($0.56)
Weighted Average Basic Shares Outstanding		 8.50M 11.68M 15.06M 24.54M 66.99M
Diluted Earnings per Share		 - - - ($1.28) ($0.56)
Weighted Average Diluted Shares Outstanding		 - 15.00M 15.23M 24.54M 66.99M
Weighted Average Basic & Diluted Shares Outstanding		 - 15.00M 15.23M 34.76M 119.71M

Quarterly Income Statements for Unicycive Therapeutics

This table shows Unicycive Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.56 -5.33 -15 -4.44 -4.41 -7.80 -21 3.04 -4.10 -16 0.51
Consolidated Net Income / (Loss)		 -5.56 -5.33 -15 -3.84 -4.33 -7.80 -21 9.86 -4.10 -22 0.57
Net Income / (Loss) Continuing Operations		 -5.56 -5.33 -15 -3.84 -4.33 -7.80 -21 9.86 -4.10 -22 0.57
Total Pre-Tax Income 		-5.56 -5.33 -15 -3.84 -4.33 -7.80 -21 9.86 -4.10 -22 0.57
Total Operating Income		 -5.55 -5.33 -4.20 -4.32 -5.94 -6.31 -9.20 -7.40 -6.25 -9.26 -7.99
Total Gross Profit		 0.95 - 0.68 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.95 - 0.68 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 6.51 5.33 4.88 4.32 5.94 6.31 9.20 7.40 6.25 9.26 7.99
Selling, General & Admin Expense		 1.70 1.49 1.85 2.06 2.57 2.08 2.39 2.53 3.21 3.97 5.82
Research & Development Expense		 4.80 3.84 3.03 2.27 3.37 4.23 6.81 4.87 3.05 5.29 2.17
Total Other Income / (Expense), net		 -0.01 -0.01 -10 0.48 1.61 -1.49 -12 17 2.16 -12 8.56
Interest Expense		 0.00 0.00 0.01 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02
Interest & Investment Income		 0.00 - 0.01 0.23 0.23 0.14 0.07 0.46 0.42 0.31 0.23
Other Income / (Expense), net		 -0.00 -0.00 -10 0.28 1.40 -1.61 -12 17 1.75 -13 8.35
Basic Earnings per Share		 ($0.37) ($0.35) ($0.97) ($0.29) ($0.13) $0.11 ($0.61) $0.08 ($0.05) $0.02 $0.00
Weighted Average Basic Shares Outstanding		 15.06M 15.06M 15.23M 15.23M 32.63M 24.54M 34.91M 37.91M 88.94M 66.99M 116.82M
Diluted Earnings per Share		 - - - ($0.29) ($0.13) - ($0.61) ($0.15) ($0.05) - ($0.05)
Weighted Average Diluted Shares Outstanding		 15.09M 15.23M 15.23M 15.23M 32.63M 24.54M 34.91M 94.05M 88.94M 66.99M 123.83M
Weighted Average Basic & Diluted Shares Outstanding		 15.09M 15.23M 15.23M 34.75M 34.75M 34.76M 37.61M 94.36M 103.80M 119.71M 120.63M

Annual Cash Flow Statements for Unicycive Therapeutics

This table details how cash moves in and out of Unicycive Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -0.02 17 -16 11 20
Net Cash From Operating Activities		 -1.46 -5.77 -16 -18 -29
Net Cash From Continuing Operating Activities		 -1.46 -5.76 -16 -18 -29
Net Income / (Loss) Continuing Operations		 -2.26 -10 -18 -31 -37
Consolidated Net Income / (Loss)		 -2.26 -10 -18 -31 -37
Depreciation Expense		 0.00 0.00 0.01 0.01 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.29 3.70 1.07 12 8.15
Changes in Operating Assets and Liabilities, net		 0.33 0.06 1.18 0.16 -0.03
Net Cash From Investing Activities		 0.00 -0.03 -0.00 -0.01 -0.07
Net Cash From Continuing Investing Activities		 0.00 -0.03 -0.00 -0.01 -0.07
Purchase of Property, Plant & Equipment		 0.00 -0.03 -0.00 -0.01 -0.07
Net Cash From Financing Activities		 1.44 22 -0.47 28 45
Net Cash From Continuing Financing Activities		 1.44 22 -0.47 30 49
Repayment of Debt		 -0.16 -1.36 - 0.00 -0.16
Payment of Dividends		 - - - 0.00 -1.10
Issuance of Preferred Equity		 - - 0.00 30 50
Other Financing Activities, net		 -0.10 0.12 -0.48 -0.50 0.16
Cash Interest Paid		 - - 0.01 0.02 0.01
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Unicycive Therapeutics

This table details how cash moves in and out of Unicycive Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -3.56 -6.56 24 -5.51 -4.47 -2.49 39 -7.15 -5.62 -6.21 -6.37
Net Cash From Operating Activities		 -3.56 -6.08 -3.92 -5.50 -4.42 -4.44 -6.46 -6.32 -9.25 -6.55 -8.90
Net Cash From Continuing Operating Activities		 -3.56 -6.08 -3.87 -5.56 -4.44 -4.45 -6.18 -6.32 -9.26 -6.55 -8.90
Net Income / (Loss) Continuing Operations		 -5.56 -5.33 -15 -3.84 -4.33 -7.80 -21 9.86 -4.10 -22 0.57
Consolidated Net Income / (Loss)		 -5.56 -5.33 -15 -3.84 -4.33 -7.80 -21 9.86 -4.10 -22 0.57
Depreciation Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 - 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 0.27 0.22 11 -0.14 -0.47 2.16 12 -16 -1.15 13 -7.79
Changes in Operating Assets and Liabilities, net		 1.69 -1.02 0.15 -1.66 0.48 1.19 2.17 0.11 -3.86 1.83 -1.69
Net Cash From Investing Activities		 - - 0.00 -0.01 - - -0.01 -0.02 -0.02 -0.02 -0.02
Net Cash From Continuing Investing Activities		 - - 0.00 -0.01 - - -0.01 -0.02 -0.02 -0.02 -0.02
Purchase of Property, Plant & Equipment		 - - 0.00 -0.01 - - -0.01 -0.02 -0.02 -0.02 -0.02
Net Cash From Financing Activities		 - -0.47 28 - -0.05 -0.21 46 -0.81 -0.16 0.37 2.55
Net Cash From Continuing Financing Activities		 - -0.47 28 0.24 -0.29 1.95 46 -0.60 3.45 0.36 2.55
Issuance of Debt		 - - - - - - - - - - 2.79
Issuance of Preferred Equity		 - - 30 - - - 50 - - - 0.00
Other Financing Activities, net		 - -0.48 -0.24 - - -0.21 -0.50 - - 0.52 -0.24
Cash Interest Paid		 - - 0.00 0.04 -0.04 0.02 0.01 -4.96 0.02 -0.04 0.01
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for Unicycive Therapeutics

This table presents Unicycive Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 0.20 19 2.82 14 32
Total Current Assets		 0.20 18 2.64 13 31
Cash & Equivalents		 0.00 17 0.46 9.70 26
Prepaid Expenses		 0.00 1.83 2.19 3.70 4.81
Plant, Property, & Equipment, net		 0.00 0.03 0.02 0.03 0.08
Total Noncurrent Assets		 0.00 0.31 0.15 0.77 0.65
Other Noncurrent Operating Assets		 0.00 0.31 0.15 0.77 0.65
Total Liabilities & Shareholders' Equity		 0.20 19 2.82 14 32
Total Liabilities		 2.88 2.26 3.28 18 24
Total Current Liabilities		 2.88 2.11 3.28 18 24
Accounts Payable		 0.19 0.74 0.89 0.84 1.06
Accrued Expenses		 0.17 1.21 2.24 3.23 3.56
Other Current Liabilities		 0.02 0.15 0.16 13 20
Total Noncurrent Liabilities		 0.00 0.16 0.00 0.47 0.12
Capital Lease Obligations		 - - 0.00 - 0.12
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -2.67 16 -0.47 -3.81 7.43
Total Preferred & Common Equity		 -2.67 16 -0.47 -3.81 7.43
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -2.67 16 -0.47 -3.81 7.43
Common Stock		 3.25 32 34 61 109
Retained Earnings		 -5.92 -16 -34 -65 -101

Quarterly Balance Sheets for Unicycive Therapeutics

This table presents Unicycive Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 13 10 27 23 19 52 45 39 28
Total Current Assets		 13 9.96 26 22 19 52 44 38 27
Cash & Equivalents		 11 7.01 24 19 14 49 42 32 20
Prepaid Expenses		 1.99 2.95 1.85 3.11 4.22 2.75 2.27 5.39 7.58
Plant, Property, & Equipment, net		 0.03 0.02 0.02 0.03 0.03 0.02 0.04 0.06 0.08
Total Noncurrent Assets		 0.23 0.19 1.00 0.92 0.85 0.69 0.60 0.77 0.52
Other Noncurrent Operating Assets		 0.23 0.19 1.00 0.92 0.85 0.69 0.60 0.77 0.52
Total Liabilities & Shareholders' Equity		 13 10 27 23 19 52 45 39 28
Total Liabilities		 2.91 5.55 17 16 16 31 13 11 17
Total Current Liabilities		 2.83 5.52 16 15 15 30 13 10 17
Accounts Payable		 0.75 2.29 0.79 0.50 1.08 1.24 1.47 0.55 1.40
Accrued Expenses		 1.93 3.07 1.70 1.69 2.53 3.55 3.12 2.99 4.14
Other Current Liabilities		 0.16 0.17 13 13 0.31 25 8.49 6.92 11
Total Noncurrent Liabilities		 0.07 0.03 0.72 0.63 12 0.37 0.27 0.27 0.00
Capital Lease Obligations		 0.07 0.03 - 0.63 0.55 0.37 0.27 0.27 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 9.91 4.63 -15 -19 3.43 -24 -15 28 11
Total Preferred & Common Equity		 9.91 4.63 -15 -19 3.39 -24 -15 28 11
Preferred Stock		 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.00
Total Common Equity		 9.91 4.63 -15 -19 3.39 -24 -15 28 11
Common Stock		 33 33 33 33 60 61 61 108 112
Retained Earnings		 -23 -29 -49 -52 -57 -86 -76 -80 -101

Annual Metrics And Ratios for Unicycive Therapeutics

This table displays calculated financial ratios and metrics derived from Unicycive Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -29.02% -100.00%
EBITDA Growth		 0.00% -385.66% -100.93% -73.59% -21.98%
EBIT Growth		 0.00% -365.74% -91.94% -72.10% -22.02%
NOPAT Growth		 0.00% -344.41% -101.09% -15.08% -54.60%
Net Income Growth		 0.00% -342.45% -80.27% -69.14% -20.25%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 56.25%
Operating Cash Flow Growth		 0.00% -295.27% -171.39% -16.82% -56.29%
Free Cash Flow Firm Growth		 0.00% 0.00% -85.56% 83.47% -784.93%
Invested Capital Growth		 0.00% 46.02% -869.47% -1,366.88% -38.50%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -16.62% -9.09% -57.90%
EBIT Q/Q Growth		 0.00% 0.00% -16.66% -9.09% -57.88%
NOPAT Q/Q Growth		 0.00% 0.00% -16.62% -4.99% -10.11%
Net Income Q/Q Growth		 0.00% 0.00% -16.64% -8.80% -59.68%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% -17.65% -42.67% 8.25% -7.97%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 66.60% 34.90%
Invested Capital Q/Q Growth		 0.00% 0.00% 60.89% -30.42% -342.13%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% -1,881.91% -4,602.67% 0.00%
Operating Margin		 0.00% 0.00% -1,898.21% -3,077.63% 0.00%
EBIT Margin		 0.00% 0.00% -1,898.84% -4,604.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% -1,898.84% -4,525.04% 0.00%
Tax Burden Percent		 100.00% 100.00% 99.97% 100.00% 100.00%
Interest Burden Percent		 112.08% 106.47% 100.03% 98.28% 96.86%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 84.76% -145.04% -225.47% 1,428.96% -2,028.11%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -167.50% -365.42% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -167.50% -359.15% 0.00%
Return on Common Equity (ROCE)		 84.76% -145.04% -225.47% 1,428.96% -2,028.11%
Return on Equity Simple (ROE_SIMPLE)		 84.76% -60.77% 3,875.11% 801.89% -494.27%
Net Operating Profit after Tax (NOPAT)		 -1.41 -6.28 -13 -15 -22
NOPAT Margin		 0.00% 0.00% -1,328.75% -2,154.34% 0.00%
Net Nonoperating Expense Percent (NNEP)		 34.07% -53.01% -63.66% -315.13% -79.50%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 381.77% -302.54%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 690.54% 1,266.22% 0.00%
R&D to Revenue		 0.00% 0.00% 1,307.68% 1,911.41% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 1,998.21% 3,177.63% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.02 -9.41 -18 -31 -38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.83 -8.91 -18 -31 -38
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 1.87 0.00 0.00 7.16
Price to Tangible Book Value (P/TBV)		 0.00 1.87 0.00 0.00 7.16
Price to Revenue (P/Rev)		 0.00 0.00 8.65 31.54 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 8.17 17.17 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 -0.93 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.93 -1.02 -1.06 2.38 -9.90
Leverage Ratio		 -0.08 1.37 1.35 -3.98 12.66
Compound Leverage Factor		 -0.09 1.46 1.35 -3.91 12.26
Debt to Total Capital		 -1,417.61% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -1,417.61% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 1,517.61% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.36 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -1.36 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.76 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -1.76 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -83.29 6.40 -36.47 -13.19 -6.85
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 0.07 8.75 0.81 0.76 1.28
Quick Ratio		 0.00 7.88 0.14 0.55 1.08
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.36 -12 -1.95 -17
Operating Cash Flow to CapEx		 0.00% -19,886.21% -782,550.00% -152,358.33% -39,687.50%
Free Cash Flow to Firm to Interest Expense		 0.00 -10.45 -1,968.40 -23.81 -243.39
Operating Cash Flow to Interest Expense		 -5.98 -9.47 -2,608.50 -222.96 -402.46
Operating Cash Flow Less CapEx to Interest Expense		 -5.98 -9.52 -2,608.83 -223.11 -403.48
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.09 0.08 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 38.04 28.13 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -0.18 -0.10 -0.92 -14 -19
Invested Capital Turnover		 0.00 0.00 -1.87 -0.09 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.08 -0.83 -13 -5.20
Enterprise Value (EV)		 30 14 7.77 12 27
Market Capitalization		 28 31 8.23 21 53
Book Value per Share		 ($0.31) $1.10 ($0.03) ($0.11) $0.11
Tangible Book Value per Share		 ($0.31) $1.10 ($0.03) ($0.11) $0.11
Total Capital		 -0.18 16 -0.47 -3.81 7.43
Total Debt		 2.50 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 2.50 -17 -0.46 -9.70 -26
Capital Expenditures (CapEx)		 0.00 0.03 0.00 0.01 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.18 -0.27 -1.10 -14 -19
Debt-free Net Working Capital (DFNWC)		 -0.18 16 -0.64 -4.14 6.83
Net Working Capital (NWC)		 -2.67 16 -0.64 -4.14 6.83
Net Nonoperating Expense (NNE)		 0.85 3.73 5.42 16 14
Net Nonoperating Obligations (NNO)		 2.50 -17 -0.46 -9.70 -26
Total Depreciation and Amortization (D&A)		 0.19 0.50 0.16 0.01 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -115.14% -2,049.78% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% -67.30% -612.59% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% -67.30% -612.59% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.86) ($1.20) ($1.28) ($0.56)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 11.68M 15.06M 24.54M 66.99M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.56)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 15.00M 15.23M 34.76M 66.99M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 15.00M 15.23M 34.76M 119.71M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.41 -6.28 -13 -15 -22
Normalized NOPAT Margin		 0.00% 0.00% -1,328.75% -2,154.34% 0.00%
Pre Tax Income Margin		 0.00% 0.00% -1,899.47% -4,525.04% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -8.28 -15.45 -3,009.67 -378.99 -534.07
NOPAT to Interest Expense		 -5.80 -10.32 -2,106.07 -177.34 -316.65
EBIT Less CapEx to Interest Expense		 -8.28 -15.50 -3,010.00 -379.13 -535.08
NOPAT Less CapEx to Interest Expense		 -5.80 -10.37 -2,106.40 -177.49 -317.66
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% -2.98%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -2.98%

Quarterly Metrics And Ratios for Unicycive Therapeutics

This table displays calculated financial ratios and metrics derived from Unicycive Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -8.07% -92.99% -315.44% -10.18% 17.71% -49.74% -42.64% 334.63% 1.08% -175.58% 101.77%
EBIT Growth		 -7.99% -93.60% -312.13% -11.11% 18.27% -48.61% -44.14% 332.90% 0.99% -175.56% 101.71%
NOPAT Growth		 -17.79% -93.50% -18.80% -18.87% -6.91% -18.54% -119.04% -144.63% -5.27% -46.72% -24.00%
Net Income Growth		 -6.84% -93.60% -312.07% -5.56% 22.03% -46.36% -43.83% 356.77% 5.47% -176.03% 102.72%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 48.28% 61.54% 0.00% 91.80%
Operating Cash Flow Growth		 -2.56% -333.64% -32.57% -80.57% -24.11% 27.04% -64.69% -14.85% -109.23% -47.51% -37.90%
Free Cash Flow Firm Growth		 89.89% 0.00% 599.91% 476.12% 966.92% 381.60% -39.40% -211.03% -372.98% -115.69% -510.46%
Invested Capital Growth		 -316.25% -869.47% -3,574.20% -1,821.15% -339.87% -1,366.88% -92.68% 10.48% 59.15% -38.50% 68.08%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -53.42% 4.19% -174.91% 72.74% -14.59% -74.34% -161.88% 144.85% -148.31% -385.68% 101.68%
EBIT Q/Q Growth		 -52.83% 4.12% -173.59% 72.29% -12.43% -74.33% -165.37% 144.78% -147.79% -385.19% 101.65%
NOPAT Q/Q Growth		 -52.75% 4.12% 21.09% -2.86% -37.39% -6.30% -45.82% -14.87% 40.88% -48.15% -23.24%
Net Income Q/Q Growth		 -52.83% 4.12% -173.55% 73.67% -12.90% -79.97% -168.83% 147.01% -141.56% -425.51% 102.65%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 55.17% 0.00% 0.00% 0.00% 66.67% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -16.93% -70.76% 35.57% -40.36% 19.63% -0.38% -45.44% 2.12% -46.42% 29.23% -35.97%
Free Cash Flow Firm Q/Q Growth		 78.43% -553.79% 461.80% -26.29% -50.28% 112.37% -22.15% -235.05% -22.25% 87.80% -1,937.14%
Invested Capital Q/Q Growth		 -298.48% 60.89% -1,400.00% 17.81% 8.76% -30.42% -97.03% 61.82% 58.36% -342.13% 54.58%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -580.13% 0.00% -2,152.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -584.02% 0.00% -622.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -584.33% 0.00% -2,159.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -584.33% 0.00% -2,159.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.95% 99.94% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.05% 100.06% 99.99% 95.00% 95.40% 98.48% 99.77% 104.74% 91.08% 98.65% 158.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -131.08% -225.47% -244.91% -350.04% -696.63% 1,428.96% -229.05% -121.76% -147.05% -2,028.11% -92.09%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -37.10% 0.00% -163.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -37.10% 0.00% -163.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -131.08% -225.47% 18.94% 197.85% -692.82% 1,428.96% 280.83% 109.15% -146.85% -2,028.11% 36.79%
Return on Equity Simple (ROE_SIMPLE)		 -334.67% 0.00% 192.92% 151.24% -828.14% 0.00% 151.01% 156.53% -82.59% 0.00% -134.82%
Net Operating Profit after Tax (NOPAT)		 -3.89 -3.73 -2.94 -3.03 -4.16 -4.42 -6.44 -7.40 -4.38 -6.48 -7.99
NOPAT Margin		 -408.81% 0.00% -435.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -13.41% -18.79% -61.31% -5.67% -1.70% -66.55% -39.96% 57.82% 1.22% -83.93% 25.13%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 116.00% 26.75% - - -87.24% -70.88%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 178.97% 0.00% 273.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 505.05% 0.00% 448.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 684.02% 0.00% 722.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.56 -5.33 -15 -4.04 -4.54 -7.92 -21 9.41 -4.50 -22 0.36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.52 -5.29 -15 -3.96 -4.54 -7.92 -21 9.30 -4.49 -22 0.37
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.92 0.00 0.00 0.00 8.28 0.00 0.00 0.00 1.30 7.16 6.32
Price to Tangible Book Value (P/TBV)		 1.92 0.00 0.00 0.00 8.28 0.00 0.00 0.00 1.30 7.16 6.32
Price to Revenue (P/Rev)		 9.36 8.65 19.67 11.99 41.58 31.54 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2.02 8.17 20.45 16.92 21.21 17.17 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 98.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.00 0.00 0.09 0.16 0.00 0.02 0.01 0.01 0.00 0.00
Long-Term Debt to Equity		 0.01 0.00 0.00 0.09 0.16 0.00 0.02 0.01 0.01 0.00 0.00
Financial Leverage		 -1.05 -1.06 -1.60 -1.71 -2.58 2.38 -2.25 -1.56 -1.47 -9.90 -2.06
Leverage Ratio		 1.27 1.35 1.81 2.13 3.67 -3.98 2.47 1.77 1.85 12.66 2.43
Compound Leverage Factor		 1.27 1.35 1.81 2.03 3.51 -3.92 2.46 1.85 1.69 12.49 3.86
Debt to Total Capital		 0.62% 0.00% 0.00% 8.49% 13.85% 0.00% 1.68% 0.87% 0.94% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.62% 0.00% 0.00% 8.49% 13.85% 0.00% 1.68% 0.87% 0.94% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 1.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 243.41% 351.05% 0.00% 0.00% 208.96% 146.09% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.38% 100.00% -143.41% -259.54% 85.05% 100.00% -110.65% -46.96% 99.06% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.02 -0.02 0.00 -0.01 -0.01 -0.01 0.00 0.00
Net Debt to EBITDA		 0.45 0.00 0.00 0.62 0.48 0.00 1.30 1.75 1.34 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.02 -0.02 0.00 -0.01 -0.01 -0.01 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.05 -0.04 0.00 -0.02 -0.01 -0.01 0.00 0.00
Net Debt to NOPAT		 0.64 0.00 0.00 1.34 1.00 0.00 2.69 2.05 1.57 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.05 -0.04 0.00 -0.02 -0.01 -0.01 0.00 0.00
Altman Z-Score		 -4.17 -21.56 -2.61 -2.65 -3.58 -7.80 -2.18 1.27 -0.40 -5.18 -1.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 107.74% 156.52% 0.55% 0.00% 222.61% 189.64% 0.14% 0.00% 139.95%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.80 0.81 1.64 1.42 1.20 0.76 1.71 3.37 3.61 1.28 1.64
Quick Ratio		 1.27 0.14 1.52 1.22 0.93 0.55 1.62 3.19 3.09 1.08 1.19
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.44 -2.90 10 7.74 3.85 8.17 6.36 -8.59 -11 -1.28 -26
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -45,850.00% 0.00% 0.00% -107,600.00% -31,595.00% -38,550.00% -29,763.64% -55,643.75%
Free Cash Flow to Firm to Interest Expense		 -147.93 -967.17 874.80 241.80 213.74 408.53 318.06 -536.94 -700.18 -64.09 -1,740.67
Operating Cash Flow to Interest Expense		 -1,187.67 -2,028.00 -326.67 -171.94 -245.67 -221.95 -322.80 -394.94 -616.80 -327.40 -593.53
Operating Cash Flow Less CapEx to Interest Expense		 -1,187.67 -2,028.00 -326.67 -172.31 -245.67 -221.95 -323.10 -396.19 -618.40 -328.50 -594.60
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.06 0.09 0.08 0.09 0.05 0.08 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 38.04 66.37 58.07 25.96 28.13 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.36 -0.92 -14 -11 -10 -14 -27 -10 -4.23 -19 -8.50
Invested Capital Turnover		 -1.50 -1.87 -0.23 -0.27 -0.11 -0.09 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.44 -0.83 -13 -11 -8.00 -13 -13 1.19 6.13 -5.20 18
Enterprise Value (EV)		 1.92 7.77 33 28 14 12 46 52 4.20 27 51
Market Capitalization		 8.90 8.23 32 20 28 21 48 47 36 53 71
Book Value per Share		 $0.31 ($0.03) ($1.00) ($1.27) $0.10 ($0.11) ($0.70) ($0.39) $0.31 $0.11 $0.10
Tangible Book Value per Share		 $0.31 ($0.03) ($1.00) ($1.27) $0.10 ($0.11) ($0.70) ($0.39) $0.31 $0.11 $0.10
Total Capital		 4.66 -0.47 11 7.46 3.99 -3.81 22 32 28 7.43 11
Total Debt		 0.03 0.00 0.00 0.63 0.55 0.00 0.37 0.27 0.27 0.00 0.00
Total Long-Term Debt		 0.03 0.00 0.00 0.63 0.55 0.00 0.37 0.27 0.27 0.00 0.00
Net Debt		 -6.98 -0.46 -24 -18 -14 -9.70 -49 -42 -32 -26 -20
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.02 0.02 0.02 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.57 -1.10 -14 -12 -11 -14 -28 -11 -5.07 -19 -9.10
Debt-free Net Working Capital (DFNWC)		 4.44 -0.64 10 6.51 3.11 -4.14 21 31 27 6.83 11
Net Working Capital (NWC)		 4.44 -0.64 10 6.51 3.11 -4.14 21 31 27 6.83 11
Net Nonoperating Expense (NNE)		 1.67 1.60 12 0.81 0.18 3.38 15 -17 -0.28 15 -8.56
Net Nonoperating Obligations (NNO)		 -6.98 -0.46 -24 -18 -14 -9.70 -48 -42 -32 -26 -20
Total Depreciation and Amortization (D&A)		 0.04 0.04 0.05 0.08 0.00 0.00 0.28 -0.11 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -270.24% -115.14% -868.27% -756.89% -1,664.00% -2,049.78% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 466.88% -67.30% 628.17% 400.43% 461.19% -612.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 466.88% -67.30% 628.17% 400.43% 461.19% -612.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.37) ($0.35) ($0.97) ($0.29) ($0.13) $0.11 ($0.61) $0.08 ($0.05) $0.02 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 15.06M 15.06M 15.23M 15.23M 32.63M 24.54M 34.91M 37.91M 88.94M 66.99M 116.82M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.15) ($0.05) $0.00 ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 15.09M 15.23M 15.23M 34.75M 34.75M 24.54M 37.61M 94.05M 88.94M 66.99M 123.83M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 15.09M 15.23M 15.23M 34.75M 34.75M 34.76M 37.61M 94.36M 103.80M 119.71M 120.63M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.89 -3.73 -2.94 -3.03 -4.16 -4.42 -6.44 -5.18 -4.38 -6.48 -5.59
Normalized NOPAT Margin		 -408.81% 0.00% -435.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -584.65% 0.00% -2,159.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1,852.33 -1,776.00 -1,214.75 -126.25 -252.33 -395.90 -1,050.60 588.06 -299.80 -1,090.95 23.93
NOPAT to Interest Expense		 -1,295.93 -1,242.50 -245.12 -94.54 -230.92 -220.92 -322.14 -462.56 -291.71 -324.14 -532.60
EBIT Less CapEx to Interest Expense		 -1,852.33 -1,776.00 -1,214.75 -126.63 -252.33 -395.90 -1,050.90 586.81 -301.40 -1,092.05 22.87
NOPAT Less CapEx to Interest Expense		 -1,295.93 -1,242.50 -245.12 -94.92 -230.92 -220.92 -322.44 -463.81 -293.31 -325.24 -533.67
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.98% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.98% 0.00%

Financials Breakdown Chart

Key Financial Trends

Unicycive Therapeutics (NASDAQ: UNCY) remains in a pre-revenue, cash-consuming stage, but its latest quarterly results show a notable shift in the income statement thanks to large non-operating gains. The core operating picture is still weak: the company generated no revenue in Q1 2025 and posted $7.99 million in operating expenses, leading to an operating loss of $7.99 million. However, other income was strong enough to produce net income of $0.57 million for the quarter.

That profit should be viewed cautiously, though, because it was not driven by the core business. On the cash flow side, UNCY still burned cash from operations, with negative operating cash flow of $8.90 million in Q1 2025. The company also used modest cash for investing, while financing activities brought in $2.55 million, partially offsetting the burn. Even so, cash still fell by $6.37 million during the quarter.

The balance sheet is the key area to watch. As of March 31, 2025, UNCY reported $19.77 million in cash and equivalents against $16.68 million in total liabilities, leaving a thinner margin than it had at the end of 2024. Cash has declined meaningfully from $32.35 million at Q3 2024 and $48.93 million at Q1 2024, underscoring continued funding pressure.

Looking at the last four years, the trend is mixed: operating losses have generally remained substantial, share count has risen over time, and the company has repeatedly relied on financing to support operations. The one bright spot is that UNCY has recently had some quarters with unusually large “other income” items that can swing reported earnings sharply from loss to profit. For investors, the main question is whether the company can convert its pipeline progress into recurring revenue before cash needs become more pressing.

  • Q1 2025 reported net income of $570,000, a sharp improvement from the $21.5 million loss in Q4 2024.
  • The company ended Q1 2025 with $19.77 million in cash, giving it some near-term liquidity.
  • Financing activities added $2.55 million in Q1 2025, helping cushion operating cash burn.
  • Operating expenses in Q1 2025 were $7.99 million, down from $9.26 million in Q4 2024.
  • Q1 2025 still included meaningful non-operating support, with $8.56 million in other income/expense, net.
  • Revenue remained $0 in Q1 2025, so the company is still not generating sales.
  • Core operations remained deeply unprofitable, with negative operating cash flow of $8.90 million in Q1 2025.
  • Cash and equivalents fell from $32.35 million in Q3 2024 to $19.77 million in Q1 2025.
  • Total liabilities stood at $16.68 million, which is sizable relative to the company’s cash balance.
  • Over the longer term, UNCY has relied on external financing and share-based capital raises to fund operations.

Overall, UNCY’s latest quarter looks better on paper than the prior quarter because of non-operating gains, but the underlying story is still one of cash burn, no revenue, and dependence on financing. For retail investors, that makes the stock highly event-driven and tied to clinical or regulatory milestones rather than traditional fundamental strength.

06/04/26 02:24 AM ETAI Generated. May Contain Errors.

Unicycive Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Unicycive Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Unicycive Therapeutics' net income appears to be on an upward trend, with a most recent value of -$36.73 million in 2024, rising from -$2.26 million in 2020. The previous period was -$30.54 million in 2023. Check out Unicycive Therapeutics' forecast to explore projected trends and price targets.

Unicycive Therapeutics' total operating income in 2024 was -$32.12 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $32.12 million

Over the last 4 years, Unicycive Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

Unicycive Therapeutics' total liabilities were at $24.24 million at the end of 2024, a 34.7% increase from 2023, and a 743.0% increase since 2020.

In the past 4 years, Unicycive Therapeutics' cash and equivalents has ranged from $0.00 in 2020 to $26.14 million in 2024, and is currently $26.14 million as of their latest financial filing in 2024.

Over the last 4 years, Unicycive Therapeutics' book value per share changed from -0.31 in 2020 to 0.11 in 2024, a change of -135.3%.


Related Companies

Financial statements for NASDAQ:UNCY last updated on 6/20/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A gold storm is coming – are you ready?
The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...
Traders Agency | Sponsoredtc pixel
The SpaceX S-1 changes everything
SpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...
Crypto 101 Media | Sponsoredtc pixel
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...
Behind the Markets | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel